TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03489876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthetic Cartilage Implant
Description: The Synthetic Cartilage Implant will be implanted in to the first metatarsal head according to the manufacturer's recommendations.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteochondral Autograft Transfer
Description: The osteochondral autograft transfer will be harvested from the ipsilateral lateral femoral condyle (or contralateral if a previous ipsilateral total knee anthroplasty or trauma) and the graft will be transferred to the first metatarsal head.
Study: NCT04296968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Painful stimulation using a laser device (DEKA Stimul 1340, Calenzano, Italy)
Description: In the experimental paradigm, 160 painful stimuli of two intensities (3 J, 3.5 J) will be applied to the dorsum of the left hand using the laser device listed above.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual cueing
Description: Preceding to each painful stimulus, visual cues (e.g., blue dot and yellow square) will be presented on a screen indicating the intensity of the subsequent stimulus (low and high intensity) with an accuracy of 75%. The contingencies of the visual cues will be explicitly stated to the participants.
Study: NCT02671110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transforming Your Life
Description: See Transforming Your Life Arm

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Program
Description: See Diabetes Prevention Program Arm
Study: NCT01907269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-based Intervention
Description: Video clips delivered by DVD and Internet
Study: NCT00490698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronate
Description: 4 mg IV Once Every 4 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 20 mg PO Daily
Study: NCT03805477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib 150 mg Kps bid (oral); in order to manage adverse events, the dose of Nintedanib may be reduced from 150 mg twice daily to 100 mg twice daily
Study: NCT03542110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alirocumab 150 MG/ML subcutaneous injection
Description: Single-dose, pre-filled, disposable, subcutaneous injection pen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo subcutaneous injection
Description: Single-dose, pre-filled, disposable, subcutaneous injection pen
Study: NCT03772769

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Target Enriched Multiplex PCR (TEM- PCR)
Description: Target Enriched Multiplex PCR (TEM- PCR) assays will be performed and will probe for the typical array of advanced deep space odontogenic infections, as well as MRSA resistance, clindamycin resistance, and the presence of Panton-Valentine leukocidin (PVL) toxin, a toxin produced by some bacteria.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microbial culture
Description: Standard diagnosis by microbial culture.
Study: NCT02737813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isobaric marcaine
Description: Isobaric marcaine 2.2 mL for spinal block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric marcaine
Description: Hyperbaric marcaine 2.2 mL for spinal block
Study: NCT03243435

Intervention type: PROCEDURE
Intervention: Native 1,5 Tesla breast MRI
Study: NCT01607151

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normothermia
Description: 72 hours of targeted temperature management to achieve normothermia (36-37°C)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: 72 hours of targeted temperature management to achieve hypothermia (32-34°C)
Study: NCT03006640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous nitroglycrin
Description: In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous saline
Description: In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
Study: NCT03821467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual beam Doppler Fourier-domain OCT (DOCT)
Description: Retinal blood flow will be assessed using DOCT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Retinal vessel diameters and oxygen saturation will be measured with the DVA device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Description: Retinal morphology will be imaged using OCT.
Study: NCT01499563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-007
Description: Capsules containing ITI-007 for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-007
Description: Capsules containing ITI-007 for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules containing inactive placebo for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing inactive placebo for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Capsules containing risperidone for 28 days
Study: NCT04554641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasted breath samples
Description: Participants will provide fasted breath samples pre and post Bio-Kult Advanced.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily Diary
Description: Monitoring stool form, consistency and frequency on a daily basis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stool sample
Description: Participants will provide stool sample pre and post Bio-kult Advanced.
Study: NCT01607541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCAP peer-driven intervention (PDI)
Description: The Brooklyn Community Action Project (BCAP) PDI entails structured sessions including the computerized CARE for Prevention tool, 3 peer education experiences, and 6 months of navigation for those HIV infected (if HIV-negative: total 3.5 hours of facilitated/computer intervention activities, plus peer education experiences; if HIV-positive: 5 hrs facilitated/computer activities, plus peer education experiences and navigation).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: The control arm will receive a time- and attention-matched HIV counseling and testing intervention and for those found HIV-infected, an appointment with HIV services and reminders, the current standard of care.
Study: NCT01864460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification
Description: Structured weight loss or weight maintenance and aerobic exercise intervention for 12 months or standard of care weight and exercise management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle modification
Description: Structured weight loss or weight maintenance and aerobic exercise intervention for 12 months or standard of care weight and exercise management
Study: NCT00531089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered on weeks 1, 2, 3, and 4 at a dose of 375 mg/m2 per infusion. Premedications (prednisone 50 mg, diphenhydramine 50 mg, acetaminophen) will be administered prior to study infusion. Patients will also be treated with plasma exchange as per institution/apheresis centre.
Study: NCT03749304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANI monitor
Description: experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index
Study: NCT02035696

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine (TIVc)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine (TIVc)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine (TIVc)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine-licensed
Description: Licensed influenza vaccine
Study: NCT01643070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine, Oxaliplatin
Description: Induction chemotherapy - Capecitabine (1250 mg/m2 PO twice daily on D1-14 and oxaliplatin 130 mg/m2 on D1, every 3 weeks for 2 cycles) Preoperative chemoradiotherapy - Capecitabine 825 mg/m2 PO twice daily during radiotherapy and oxaliplatin 50 mg/m2/day on weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine, Oxaliplatin
Description: Induction chemotherapy - Capecitabine (1250 mg/m2 PO twice daily on D1-14 and oxaliplatin 130 mg/m2 on D1, every 3 weeks for 2 cycles) Preoperative chemoradiotherapy - Capecitabine 825 mg/m2 PO twice daily during radiotherapy and oxaliplatin 50 mg/m2/day on weekly.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Preoperative radiotherapy, 5040 cGy with 28 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Preoperative radiotherapy, 5040 cGy with 28 fractions
Study: NCT00551746

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Purple Grape Juice
Description: Grape Juice
Study: NCT02414217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person Diabetes Numeracy Education
Description: Participants randomized to the in-person education group attended four group classes, each addressing a specific set of diabetes self-care skills (i.e., understanding and using blood glucose numbers, counting carbohydrates, taking medications at the right dose and time). So that each class included a stable group of 8 and 16 participants, we ran classes in cohorts of 8-16 people. A participant always attended classes with his/her cohort.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Diabetes Numeracy Education
Description: Participants randomized to the online education group attended a single session, at which he/she completed a computerized education module that addressed understanding blood sugar values and using them to examine the impact of food, exercise, and medicines on blood sugar.
Study: NCT01404949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin and Arsenic Trioxide
Description: See Detailed Description
Study: NCT01557192

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Field Magnetic Stimulation Device
Description: The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain lasting twenty minutes. Subjects will be given one 20 minute exposure to either the LFMS or sham electromagnetic field treatment.
Study: NCT00551746

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Purple Grape Juice
Description: Grape Juice
Study: NCT03243097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase I - Standard Microphone Cros Input
Description: Subject will be fit with the research processor plus CROS microphone and wear for a 4 week period

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase II - Automatic directional microphone Cros Input
Description: Automatic directional microphone technology will be activated in the research processor. Subjects will wear the CI+CROS configuration with directionality activated exclusively for 4-weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase III - No Cros Input
Description: Subjects will return the research processor and CROS device and wear their own processor for a 2-week period
Study: NCT02672449

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon Ions Boost Followed by Pelvic Photon Radiotherapy
Description: The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, at the Division of Radiation Oncology of the European Institute of Oncology (IEO), Milan, Italy, or at the Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy. The treatment will include a boost phase on the whole prostate with carbon ions performed at CNAO followed by a pelvic photon RT, with IMRT performed with conventional fractionation of 1.8 Gy per fraction up to 45 Gy to the pelvic lymph nodes, prostate and seminal vesicles. The total dose prescribed to the prostate boost with carbon ions will be of 16.6 GyE in 4 fractions (4.15 GyE/fraction).
Study: NCT04169191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: Cohort 1 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, and subsequent doses of 2.5mg/kg/dose q12h (= 5 mg/kg/day from dose #2) Cohort 2 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, 3rd dose of 3mg/kg/dose, and subsequent doses of 3mg/kg/dose q12h (= 6 mg/kg/day from dose #3) dose expansion phase in up to 5-15 asphyxiated neonates
Study: NCT02209753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRB 796 BS, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRB 796 BS, medium dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRB 796 BS, medium dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRB 796 BS, high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00855790

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: evaluate the effectiveness of the RJ4 biopsy forcep versus the RJ3 biopsy forcep
Description: Use of either the RJ3 or RJ4 biopsy forcep for colon polypectomy. will evaluate the effectiveness of removal of polyps less than 6 mm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: evaluate the effectiveness of the RJ4 biopsy forcep versus the RJ3 biopsy forcep
Description: Use of either the RJ3 or RJ4 biopsy forcep for colon polypectomy. will evaluate the effectiveness of removal of polyps less than 6 mm.
Study: NCT03249870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (INO)
Description: INO schedule of administration is as follows:~* First induction course: 0.8 mg/m² on day 1, 0.5 mg/m² on day 8, and 0.5 mg/m² on day 15~* Second induction course: 0.5 mg/m² on day 1, and 0.5 mg/m² on day 8
Study: NCT00986596

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: 4000 IU once daily by mouth for 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)
Study: NCT01177956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: The initial dose of cetuximab will be 400 milligram per square meter (mg/m\^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m\^2 as an IV infusion over 60 minutes.~Chemotherapy will be continued for up to a maximum of six 3-week cycles in the absence of progressive disease (PD) or unacceptable toxicity. All subjects will receive cetuximab treatment until the occurrence of PD or unacceptable toxicity to cetuximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Subjects will receive 75 mg/m\^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Subjects will receive 750 mg/m\^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 5 of each 3-week treatment cycle.
Study: NCT04259697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical pilates
Description: Clinical pilates exercises will be performed progressively. The duration of each exercise session will be an average of 40 minutes initially and then will be increased to 60 minutes as the program progress.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: Whole body vibration exercises will be performed using the Power Plate pro5 AIRdaptive machine.The duration of each exercise session will be an average of 20 minutes initially and then will be increased to 30 minutes as the program progress.
Study: NCT00003622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Study: NCT01197612

Intervention type: DRUG
Group type: OTHER
Intervention: pulmicort
Description: applied to nasal packing after surgery
Study: NCT04536389

Intervention type: PROCEDURE
Intervention: Office Hysteroscopy
Description: The hysteroscope with its light source and flowing fluid was gently introduced into the vagina allowing for gradual distention. Once this was accomplished, the anatomy was followed with delicate movements. The hysteroscope was advanced under vision to the level of the ectocervix, and guided into the endocervical canal. Once the endocervical canal was completely explored, the endoscope was advanced across the internal cervical os to allow evaluation of the panoramic view of the uterine cavity.~hysteroscopic correction of any detected lesion will be scheduled to the endoscopic operative list or the patient will receive the appropriate medical treatment.

Intervention type: PROCEDURE
Intervention: Office Hysteroscopy
Description: The hysteroscope with its light source and flowing fluid was gently introduced into the vagina allowing for gradual distention. Once this was accomplished, the anatomy was followed with delicate movements. The hysteroscope was advanced under vision to the level of the ectocervix, and guided into the endocervical canal. Once the endocervical canal was completely explored, the endoscope was advanced across the internal cervical os to allow evaluation of the panoramic view of the uterine cavity.~hysteroscopic correction of any detected lesion will be scheduled to the endoscopic operative list or the patient will receive the appropriate medical treatment.
Study: NCT03944642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding support
Description: Breastfeeding self-efficacy enhancing through professional support
Study: NCT01992367

Intervention type: DRUG
Group type: OTHER
Intervention: ASLAN003 ACTIVE
Description: This is a single-centre, placebo-controlled, randomised, double-blind study involving SAD and MAD of ASLAN003 in healthy subjects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASLAN003 ACTIVE
Description: This is a single-centre, placebo-controlled, randomised, double-blind study involving SAD and MAD of ASLAN003 in healthy subjects.
Study: NCT04586166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RP Sling
Description: Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIS
Description: Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure.
Study: NCT00837590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronic salsalate
Description: Subjects will receive 2 months of treatment with 4 gram/day of oral salsalate divided into 3 doses.
Study: NCT01557192

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low Field Magnetic Stimulation Device
Description: The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain lasting twenty minutes. Subjects will be given one 20 minute exposure to either the LFMS or sham electromagnetic field treatment.
Study: NCT00779987

Intervention type: DRUG
Group type: OTHER
Intervention: Autologous serum - Systane
Description: 20% autologous serum solution used four times a day for two weeks. Then 0.9% sodium chloride four times a day for one week. Finally, Systane (r) four times a day for two weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Systane - Autologous serum
Description: Systane (r) four times a day for two weeks. Then 0.9% sodium chloride used four times a day for one weeks. Finally, 20% autologous serum solution four times a day for two week.
Study: NCT00311753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certoparin
Description: Low-molecular-weight heparin, Certoparin (3000 U anti-Xa once daily) treatment period of 10 ± 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: 7500 IU of unfractionated heparin administered twice daily during the treatment period of 10 ± 2 days
Study: NCT00837590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronic salsalate
Description: Subjects will receive 2 months of treatment with 4 gram/day of oral salsalate divided into 3 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acute Salsalate
Description: Subjects will receive a single oral dose of 2 gram of oral salsalate
Study: NCT03550079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fixation
Description: treated with different fixation method

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fixation
Description: treated with different fixation method
Study: NCT00476242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivitrol
Description: intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vivitrol
Description: intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine
Description: Memantine will be given in two divided doses, starting with the second day of the naltrexone induction, with the target doses of 40 mg/day (or the maximum tolerated dose), for a total of twelve weeks of medication treatment.
Study: NCT00128297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pamidronate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamidronate
Study: NCT02344589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: used for the active blocks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: used for the active blocks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: used for the active blocks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: used for the active blocks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: used for the placebo-block
Study: NCT03450616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO Negative Pressure Wound Therapy
Description: Negative Pressure Wound Therapy Device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Dressing
Description: Standard of Care Compression Dressing